Paraproteinemic neuropathies
- 24 May 2024
- journal article
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 29 (2) , 4-16
Abstract
Paraproteinemic polyneuropathies (PPN) occur generally infrequently and arise from diseases, associated with formation and accumulation of a pathological protein, commonly known as paraprotein, which is typically an immunoglobulin or its free light chain. Such diseases include the following: monoclonal gammopathy of undetermined significance, multiple myeloma, Waldenström’s macroglobulinemia, AL amyloidosis, POEMS syndrome, etc. Diagnosis of PPN is challenging due to nonspecific, indistinct or atypical clinical manifestation, and it is necessary to apply specialized laboratory methods, including immunochemical analysis of blood and urine. Moreover, medications can cause symptoms of polyneuropathy themselves. Thus, it is important to suspect the first symptoms of the disease in time, determine the mechanism of damage to nerve fibers, carry out differential diagnosis and initiate therapy targeting the suppression of pathological protein synthesis.Keywords
This publication has 51 references indexed in Scilit:
- Pathogenesis and treatment of multiple myelomaMedcomm, 2022
- Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline ConsortiumClinical Lymphoma Myeloma and Leukemia, 2022
- Castleman diseaseNature Reviews Disease Primers, 2021
- Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and TreatmentOncology and Therapy, 2021
- POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2021
- Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2020
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathyJournal of Neurology, 2020
- Efficacy and Safety of Rituximab in Vasculitic Neuropathy: A Systematic Review of the LiteratureReumatología Clínica (English Edition), 2019
- POEMS syndrome: clinical updateJournal of Neurology, 2018
- European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasLeukemia, 2018